Method and dosage form for treatment of premenstrual syndrome

• US 5,140,021 A
• Filed: 10/27/1989
• Issued: 08/18/1992
• Est. Priority Date: 04/16/1986
• Status: Expired due to Term

• Current Assignee: System General Corporation (ON Semiconductor Corporation)
• Original Assignee: System General Corporation (ON Semiconductor Corporation)
• Inventors: Meyers, Philip G., Maxson, Wayne S., Hargrove, Joel T.
• Primary Examiner(s): Waddell, Frederick E.
• Assistant Examiner(s): Jordan, Kimberly R.
• Application Number:
  US07/427,718
• Time in Patent Office: 1,026 Days
• Field of Search: 514/177, 514/522
• US Class Current: 514/177
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61K 9/14 Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51
• CPC Class Codes: A61K 9/4858 Organic compounds

Abstract

A pharmaceutical composition suitable for oral administration comprises micronized progesterone in an oil vehicle which is high in glycerides of polyunsaturated fatty acids. Micronized progesterone particles suspended in such an oil vehicle are absorbed more readily into the bloodstream and achieve high progesterone blood serum levels. The pharmaceutical composition according to the invention can be readily formulated into capsules and administered for the treatment of premenstrual syndrome.

Claims

1. A method of treating premenstrual syndrome, comprising orally administering to a woman suffering from premenstrual syndrome a therapeutically effective amount of an oral dosage form of progesterone comprising a suspension of micronized progesterone in an edible oil consisting essentially of not more than about 16 wt. % of saturated fatty acid glycerides, and the balance is essentially at least two glycerides of oleic, linoleic, and linolenic acids, said suspension being contained in a pharmacologically acceptable capsule, wherein said dosage form is administered over a period of consecutive days during the second half of the menstrual cycle between ovulation and menstruation in a dosage sufficient to increase blood serum levels of progesterone to at least 10 ng/ml.

2. The method of claim 1, wherein said oral dosage form of progesterone consists essentially of a suspension of micronized progesterone particles having particle sizes of less than about 10 microns, a majority of said particles having particle sizes of less than about 5 microns, and the amount of said oil is in the range of about 1.5 to 2.5 ml of said oil per gram of progesterone.

3. The method of claim 2, wherein said oral dosage form is administered in an amount in the range of 200 to 600 milligrams of progesterone per day.

4. The method of claim 1, wherein said oil consists essentially of glycerides of polyunsaturated fatty acids.

5. The method of claim 1, wherein said oil is corn oil.

6. The method of claim 1, wherein said oil is peanut oil.

7. The method of claim 1, wherein said oil is sunflower oil.

8. The method of claim 1, wherein said oil is soybean oil.

9. The method of claim 2, wherein said capsule contains 50 to 150 milligrams of progesterone per capsule.

10. The method of claim 6, wherein said capsule contains 90 to 110 milligrams of progesterone per capsule.

11. The method of claim 1, wherein said period is about 12 days and begins about 2 days after ovulation based on a 28 day menstrual cycle.

12. A method for preparing a pharmaceutical composition comprising micronized progesterone suspended in an edible oil, said oil comprising glycerides of one or more polyunsaturated fatty acids and dissolved progesterone, which method comprises the steps of:

mixing a first quantity of progesterone with said oil;

heating the resulting mixture to dissolve said first quantity of progesterone in said oil;

cooling said mixture to a temperature sufficiently low that micronized progesterone does not dissolve in said oil;

suspending a second quantity of micronized progesterone in said oil to form said pharmaceutical composition.